NCT01118312

Brief Summary

The trial will study the effectiveness of nasal steroids for the treatment of chronic rhinitis and/or sinusitis on asthma control.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
388

participants targeted

Target at P75+ for phase_4 asthma

Timeline
Completed

Started Sep 2010

Longer than P75 for phase_4 asthma

Geographic Reach
1 country

19 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 28, 2010

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 6, 2010

Completed
4 months until next milestone

Study Start

First participant enrolled

September 1, 2010

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
6 months until next milestone

Results Posted

Study results publicly available

November 30, 2015

Completed
Last Updated

November 30, 2015

Status Verified

October 1, 2015

Enrollment Period

3.8 years

First QC Date

April 28, 2010

Results QC Date

September 24, 2015

Last Update Submit

October 29, 2015

Conditions

Keywords

AsthmaRhinitisSinusitisChronicACRCSTANNasal steroidMometasoneNasal spray

Outcome Measures

Primary Outcomes (1)

  • Asthma Control Test (ACT)

    Asthma Control Test for adults (score range: 5-25); higher score indicates better asthma control

    24 weeks

Secondary Outcomes (1)

  • Childhood Asthma Control Test

    24 weeks

Study Arms (2)

Nasal Steroid

ACTIVE COMPARATOR

Intranasal mometasone, 1 spray (age \< 12 yr) or 2 sprays (age \>= 12 yrs) each nostril once a day

Drug: Mometasone Furoate monohydrate

Placebo

PLACEBO COMPARATOR

Intranasal placebo, 1 spray (age \< 12 yr) or 2 sprays (age \>= 12 yrs) each nostril once a day

Other: Placebo

Interventions

Intranasal mometasone, 1 spray (age \< 12 yr) or 2 sprays (age \>= 12 yrs) each nostril once a day for 6 months

Also known as: Nasonex
Nasal Steroid
PlaceboOTHER

Intranasal placebo spray

Placebo

Eligibility Criteria

Age6 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Physician diagnosed asthma
  • At least 12% increase in forced expiratory volume at one second (FEV1) after 2-4 puffs of albuterol or positive methacholine challenge (20% fall in FEV1 at less than 16 mg/ml methacholine); either of these can be available from the last 2 years before enrollment
  • Poorly controlled asthma as documented by a score of 19 or less on the Asthma Control Test (ACT) for participants 12 and older, and a Childhood Asthma Control Test (C-ACT) for 6-11 years(both V1 and V2).
  • Chronic symptoms of rhinitis and sinusitis as measured by a mean score of 1 on the Sino-nasal questionnaire
  • Males and females, age 6 and older

You may not qualify if:

  • Co-morbidity that predisposes to complicated rhino-sinusitis (e.g., cystic fibrosis, insulin dependent diabetes mellitus, immunodeficiency disorder)
  • Chronic diseases (other than asthma) that in the opinion of the investigator would prevent participation in the trial or put the participant at risk by participation, e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney or nervous system.
  • History of sinus surgery in last 6 months
  • Systemic/nasal steroids within last 4 weeks
  • Anti-leukotriene medication
  • History of upper airway symptoms for less than 8 weeks at the time of enrollment
  • Fever \> 38.3 degrees Celsius or patient history of fever in last 10 days
  • Greater than 10 pack year smoking history or active smoking within the last 6 months
  • FEV1 \< 50% predicted
  • Females of childbearing potential that are pregnant or lactating, or unwilling to practice an adequate birth control method
  • Allergy or intolerance to nasal mometasone
  • Cataracts, history of glaucoma, or other conditions resulting in increased intraocular pressure
  • Any investigational drug in the last 6 weeks
  • Inability to comply with study procedures, including:
  • Inability or unwillingness to provide informed consent (or assent in the case of a minor)
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (19)

University of Arizona

Tucson, Arizona, 85724, United States

Location

University of California, San Diego

San Diego, California, 92103, United States

Location

National Jewish Health

Denver, Colorado, 80206, United States

Location

Nemours Children's Clinic

Jacksonville, Florida, 32207, United States

Location

Univeristy of Miami School of Medicine

Miami, Florida, 33136, United States

Location

University of South Florida College of Medicine

Tampa, Florida, 33613, United States

Location

Northwestern Memorial Hospital

Chicago, Illinois, 60612, United States

Location

Indiana University

Indianapolis, Indiana, 46202, United States

Location

Louisiana State University Health Sciences Center

New Orleans, Louisiana, 70112, United States

Location

University of Missouri, Kansas City School of Medicine

Kansas City, Missouri, 64108, United States

Location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

North Shore-Long Island Jewish Health System

New Hyde Park, New York, 11040, United States

Location

New York University School of Medicine

New York, New York, 10016, United States

Location

New York Medical College

Valhalla, New York, 10595, United States

Location

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location

Davis Heart and Lung Research Institute

Columbus, Ohio, 43210, United States

Location

Baylor College of Medicine

Houston, Texas, 77030, United States

Location

Vermont Lung Center at the University of Vermont

Burlington, Vermont, 05405, United States

Location

Univeristy of Virginia

Charlottesville, Virginia, 22908, United States

Location

Related Links

MeSH Terms

Conditions

AsthmaRhinitisSinusitisBronchiolitis Obliterans Syndrome

Interventions

Mometasone Furoate

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesRespiratory Tract InfectionsInfectionsNose DiseasesOtorhinolaryngologic DiseasesParanasal Sinus DiseasesOrganizing PneumoniaBronchiolitis ObliteransBronchiolitisBronchitisGraft vs Host Disease

Intervention Hierarchy (Ancestors)

PregnadienediolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Results Point of Contact

Title
Razan Yasin
Organization
Johns Hopkins University

Study Officials

  • Anne Dixon, MD

    University of Vermont

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 28, 2010

First Posted

May 6, 2010

Study Start

September 1, 2010

Primary Completion

June 1, 2014

Study Completion

June 1, 2015

Last Updated

November 30, 2015

Results First Posted

November 30, 2015

Record last verified: 2015-10

Locations